But due to the formation of resistant lineage and VEGF-VEGFR2-Neuropilin-1 autocrine signaling dominance over time, the clinical benefit lasted for a short period and later resulted in tumor relapse [107, 109]. This evidence concerns the gene VEGFA and neoplasm.